- Home
- PTCT
as 05-30-2025 3:41pm EST
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | WARREN |
| Market Cap: | 3.7B | IPO Year: | 2013 |
| Target Price: | $62.31 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 7.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $28.72 - $58.38 | Next Earning Date: | 05-06-2025 |
| Revenue: | $1,772,758,000 | Revenue Growth: | 91.12% |
| Revenue Growth (this year): | 99.06% | Revenue Growth (next year): | -46.12% |
Stock Insider Trading Activity of PTC Therapeutics Inc. (PTCT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Klein Matthew B. | PTCT | CHIEF EXECUTIVE OFFICER | Apr 22 '25 | Sell | $48.74 | 2,804 | $136,655.74 | 273,234 | |
| Golden Lee Scott | PTCT | EVP & CHIEF MEDICAL OFFICER | Apr 2 '25 | Sell | $46.95 | 897 | $42,114.15 | 75,997 | |
| Pauwels Eric | PTCT | CHIEF BUSINESS OFFICER | Mar 14 '25 | Sell | $56.61 | 11,220 | $630,104.40 | 79,402 | |
| Okey Stephanie | PTCT | Director | Mar 13 '25 | Sell | $54.00 | 5,000 | $270,000.00 | 8,867 | |
| Boulding Mark Elliott | PTCT | EXEC. VP AND CLO | Mar 12 '25 | Sell | $53.27 | 15,521 | $827,232.91 | 103,901 | |
| Boulding Mark Elliott | PTCT | EXEC. VP AND CLO | Mar 10 '25 | Sell | $52.93 | 75,420 | $4,003,304.97 | 103,901 | |
| Jacobson Allan Steven | PTCT | Director | Mar 4 '25 | Sell | $51.52 | 1,230 | $63,369.60 | 19,118 |
Latest PTC Therapeutics Inc. News
PTCT Breaking Stock News: Dive into PTCT Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
Those who invested in PTC Therapeutics (NASDAQ:PTCT) three years ago are up 51%
Insider Monkey
20 days ago
PTC Therapeutics, Inc. (PTCT): Among Billionaire David E. Shaw’s Small-Cap Stock Picks with Huge Upside Potential
MT Newswires
21 days ago
BofA Upgrades PTC Therapeutics to Buy From Neutral, Adjusts Price Target to $68 From $55
MT Newswires
23 days ago
Citigroup Upgrades PTC Therapeutics to Neutral From Sell, Adjusts Price Target to $40 From $50
Associated Press Finance
23 days ago
PTC Therapeutics: Q1 Earnings Snapshot
MT Newswires
24 days ago
PTC Therapeutics Swings to Q1 Earnings, Revenue Increases
GuruFocus.com
24 days ago
PTC Therapeutics Inc (PTCT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...
PR Newswire
24 days ago
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Compare PTCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PTCT PTC Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.